Recruiting

Testing a two-drug combination for untreated blood cancer in older adults

Plain-English translation of NCT07117422 on ClinicalTrials.gov ↗ · Source last updated August 2025 · Translation generated June 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing venetoclax combined with decitabine in older patients or those who cannot tolerate standard chemotherapy for acute myeloid leukemia (AML), a serious blood cancer. Researchers believe this two-drug combination may help more patients achieve remission and live longer. The study uses a shorter 3-day dosing schedule to improve both effectiveness and tolerability.

Current treatments for AML in elderly or frail patients don't work well enough—most patients survive less than a year. While this medication combination has shown promise, the researchers want to find the best dosing strategy to improve cure rates, reduce side effects, and help more patients achieve long-term remission.

Do you qualify?

You likely qualify if…

you are age 65 or older and unwilling to receive intensive chemotherapy, OR you are over 18 and unable to handle standard chemotherapy due to heart problems, lung problems, kidney problems, or poor overall health
you have been newly diagnosed with acute myeloid leukemia (excluding certain rare subtypes) and have never received treatment for AML before
you have adequate liver, kidney, and heart function as measured by recent blood tests and heart assessments
you are willing to use effective contraception during treatment and for 3 years after, and women of childbearing potential have a negative pregnancy test
you have an expected lifespan of at least 2 months and can provide informed consent or have a legal guardian who can consent for you

You likely don't qualify if…

you have been previously treated with chemotherapy for AML, even if your previous treatment did not work
you have certain genetic forms of AML, such as those with specific chromosome changes or BCR-ABL fusion
you have secondary AML that developed after earlier blood disorders like myelodysplastic syndrome or came from prior cancer treatments
you have a known allergy or hypersensitivity to either of the two study medications
you have active untreated infections, uncontrolled heart disease, a recent heart attack (within 6 months), or are pregnant or breastfeeding

What participation looks like

You will take the two medications by mouth as part of this treatment plan designed specifically for older or frail patients. The study will involve regular visits to the hospital or clinic for blood tests, heart monitoring, and check-ups to see how well the treatment is working and to watch for any side effects. The exact schedule and duration of treatment will be explained by the research team, but the goal is to help your body fight the cancer while keeping side effects manageable.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Testing a two-drug combination for untreated blood cancer in older adults

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)